• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Autolus Therapeutics plc - American Depositary Shares (NQ: AUTL )

    2.300 -0.060 (-2.54%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 13, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 950,932
    Open 2.310
    Bid (Size) 2.310 (20)
    Ask (Size) 2.450 (1)
    Prev. Close 2.360
    Today's Range 2.230 - 2.330
    52wk Range 2.070 - 7.370
    Shares Outstanding 52,346,231
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Autolus Therapeutics Provides Business Updates and 2025 Overview
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
    From Autolus Therapeutics plc
    Via GlobeNewswire

    Performance

    YTD
    -12.55%
    -12.55%
    1 Month
    -10.85%
    -10.85%
    3 Month
    -44.98%
    -44.98%
    6 Month
    -48.31%
    -48.31%
    1 Year
    -68.10%
    -68.10%

    More News

    Read More
    Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Earnings Scheduled For November 12, 2024
    Via Benzinga
    A Glimpse Into The Expert Outlook On Autolus Therapeutics Through 5 Analysts
    Via Benzinga
    This InterContinental Hotels Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
    Via Benzinga
    Nvidia To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Tuesday
    Via Benzinga
    Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Why Revelation Biosciences Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress
    From Autolus Therapeutics plc
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024
    From Autolus Therapeutics plc
    Via GlobeNewswire
    AUTL Stock Earnings: Autolus Therapeutics Misses EPS for Q2 2024
    Via InvestorPlace
    Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
    Via InvestorPlace
    Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Crude Oil Gains 1%; GameStop Shares Plunge
    Via Benzinga
    Exposures Fossil Fuels
    Why Cracker Barrel Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    AUTL Stock Earnings: Autolus Therapeutics Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.